Table 2 Blood biochemistry and arterial stiffness before and after saxagliptin treatment
| Â | Visit 1 | Visit 2 | Visit 3 | p-value* |
|---|---|---|---|---|
Blood biochemistries | ||||
Glucose | ||||
Placebo | 114.8 ± 5.3 | 113.8 ± 5.5 | 112.1 ± 4.8 | 0.233 |
Saxagliptin | 125.9 ± 7.8 | 113.5 ± 7.6 | 117.1 ± 5.8 | |
BUN | ||||
Placebo | 14.0 ± 0.9 | 13.0 ± 0.8 | 13.7 ± 0.7 | 0.205 |
Saxagliptin | 13.1 ± 0.7 | 13.9 ± 0.8 | 13.5 ± 0.8 | |
Serum creatinine | ||||
Placebo | 1.2 ± 0.3 | 1.0 ± 0.1 | 0.9 ± 0.1 | 0.118 |
Saxagliptin | 0.9 ± 0.0 | 0.9 ± 0.0 | 0.8 ± 0.0 | |
eGFR | ||||
Placebo | 93.7 ± 3.6 | 93.0 ± 3.8 | 92.7 ± 3.9 | 0.357 |
Saxagliptin | 98.3 ± 3.1 | 93.4 ± 2.7 | 26.9 ± 2.9 | |
Cholesterol | ||||
Placebo | 174.5 ± 9.9 | 166.0 ± 7.1 | 164.3 ± 7.0 | 0.299 |
Saxagliptin | 170.1 ± 8.1 | 168.8 ± 6.6 | 171.8 ± 8.5 | |
Triglycerides | ||||
Placebo | 106.2 ± 7.3 | 112.0 ± 10.0 | 107.8 ± 7.3 | 0.972 |
Saxagliptin | 122.3 ± 13.7 | 126.5 ± 13.1 | 121.7 ± 11.3 | |
LDL/HDL | ||||
Placebo | 2.3 ± 0.2 | 2.1 ± 0.2 | 2.1 ± 0.2 | 0.160 |
Saxagliptin | 1.8 ± 0.1 | 1.8 ± 0.1 | 1.8 ± 0.2 | |
HbA1C | ||||
Placebo | 6.6 ± 0.1 | 6.6 ± 0.1 | 6.5 ± 0.1 | 0.164 |
Saxagliptin | 7.0 ± 0.2 | 6.8 ± 0.2 | 6.7 ± 0.2 | |
C-reactive protein | ||||
Placebo | 2.4 ± 0.6 | 2.9 ± 0.8 | 2.9 ± 0.7 | 0.156 |
Saxagliptin | 2.8 ± 0.5 | 2.7 ± 0.4 | 2.4 ± 0.4 | |
IL-6 | ||||
Placebo | 2.7 ± 0.6 | 4.0 ± 0.7 | 4.3 ± 0.9 | 0.629 |
Saxagliptin | 3.1 ± 0.4 | 3.9 ± 0.7 | 3.8 ± 0.8 | |
TNF-α | ||||
Placebo | 3.1 ± 0.9 | 2.8 ± 1.1 | 1.6 ± 0.2 | 0.213 |
Saxagliptin | 1.7 ± 0.2 | 1.9 ± 0.2 | 2.9 ± 1.3 | |
Leptin | ||||
Placebo | 14.1 ± 2.1 | 13.1 ± 1.8 | 13.8 ± 2.4 | 0.409 |
Saxagliptin | 19.4 ± 3.7 | 17.4 ± 2.8 | 20.4 ± 3.5 | |
Adiponectin | ||||
Placebo | 4.6 ± 0.6 | 4.9 ± 0.6 | 5.5 ± 0.6 | 0.010* |
Saxagliptin | 4.2 ± 0.6 | 4.9 ± 0.7 | 4.0 ± 0.5 | |
GLP1 (ELISA) | ||||
Placebo | 271.9 ± 67.2 | 241.1 ± 63.8 | 295.7 ± 78.5 | 0.400 |
Saxagliptin | 245.9 ± 59.0 | 245.3 ± 55.5 | 234.0 ± 58.7 | |
SDF-1É‘ (ELISA) | ||||
Placebo | − 1.84 ± 0.27 | − 1.83 ± 0.27 | − 1.80 ± 0.27 | 0.245 |
Saxagliptin | − 1.99 ± 0.27 | − 1.61 ± 0.27 | − 1.87 ± 0.25 | |
Arterial stiffness | ||||
Diastolic blood pressure (radial) | ||||
Placebo | 82.7 ± 1.8 | 82.4 ± 2.3 | 82.0 ± 2.0 | 0.3723 |
Saxagliptin | 84.9 ± 1.5 | 84.3 ± 1.2 | 81.9 ± 1.1 | |
Diastolic blood pressure (arterial) | ||||
Placebo | 84.4 ± 1.4 | 83.4 ± 2.2 | 83.1 ± 2.0 | 0.568 |
Saxagliptin | 85.4 ± 1.5 | 84.6 ± 1.1 | 82.8 ± 1.1 | |
Systolic blood pressure (radial) | ||||
Placebo | 131.8 ± 3.6 | 126.0 ± 4.3 | 134.0 ± 3.5 | 0.009* |
Saxagliptin | 132.7 ± 2.5 | 133.1 ± 1.8 | 127.7 ± 2.3 | |
Systolic blood pressure (arterial) | ||||
Placebo | 118.7 ± 3.0 | 130.0 ± 7.9 | 121.2 ± 3.3 | 0.061 |
Saxagliptin | 121.8 ± 1.7 | 117.5 ± 2.2 | 122.6 ± 2.6 | |
Augmentation index-75 | ||||
Placebo | 18.4 ± 2.4 | 26.0 ± 3.9 | 23.3 ± 2.3 | 0.037* |
Saxagliptin | 24.1 ± 2.1 | 22.5 ± 2.0 | 23.1 ± 2.1 | |